Targeting the TGF-β/Smads signaling pathway could be an effective strategy for the treatment of kidney diseases, because inhibition of the TGF-β/Smads signaling pathway ameliorates renal fibrosis and renal injury (Sun et al., 2016). Here, TGFB1 is linked to renal fibrosis.